Hokkaido University and BostonGene Expand AI-Driven Precision Oncology Collaboration
Gene, a leading developer of AI-powered solutions for tumor and immune biology, has announced the expansion of its strategic research collaboration with Hokkaido University. The multi-year initiative aims to advance precision oncology by generating clinically relevant, high-quality molecular and immune profiling data that can improve cancer treatment outcomes for patients across Japan.
The expanded collaboration represents a major step forward in the integration of artificial intelligence, genomics, and immunology into cancer research and clinical care. Through this partnership, researchers and clinicians will work together to better understand the complex biological mechanisms that drive cancer development and treatment response across a broad range of tumor types.
Under the agreement, BostonGene will leverage its proprietary AI-powered multiomics platform to analyze tumor samples collected from Japanese cancer patients. The research initiative will include next-generation sequencing and integrated analyses of DNA, RNA, and immune system profiling across more than 20 different cancer types. By combining genomic, transcriptomic, and immune-related data, the collaboration seeks to uncover disease-specific molecular signatures and identify personalized therapeutic opportunities for individual patients.
The project reflects the growing importance of precision medicine in oncology, where treatment strategies are increasingly tailored to the unique biological characteristics of each patient’s cancer. Traditional cancer treatments often rely on generalized approaches that may not account for the molecular diversity of tumors. However, advances in AI-driven analytics and multiomics technologies are enabling researchers to better understand how genetic mutations, immune responses, and tumor biology interact to influence disease progression and therapeutic outcomes.
BostonGene’s advanced analytics platform is specifically designed to transform complex biological and clinical datasets into actionable insights that can support both drug development and patient care. By integrating multiple layers of molecular and immune information, the platform can help researchers identify biomarkers, predict treatment response, and support clinical decision-making for personalized therapies.
According to researchers involved in the initiative, the collaboration will significantly strengthen efforts to bring precision oncology approaches to Japanese patients. The integrated analyses conducted during the study will help identify patient-specific disease drivers, reveal immune signatures associated with treatment response, and guide the selection of optimal therapeutic strategies.
BostonGene’s AI-powered platform gives us the advanced analytics needed to turn clinical data into actionable insights,” said Dr. Ichiro Kinoshita, Principal Investigator and Professor at the Division of Clinical Cancer Genomics and Department of Medical Oncology at Hokkaido University. “By contributing our scientific expertise and patient samples, we are helping advance a more personalized and effective approach to cancer care for patients in Japan.”
Dr. Yutaka Hatanaka, Associate Professor at the Center for Development of Advanced Diagnostics (C-DAD), Institute of Health Science Innovation for Medical Care at Hokkaido University Hospital, emphasized the importance of combining advanced diagnostics with AI-driven research capabilities. He noted that the partnership creates new opportunities to translate complex biological data into clinically meaningful insights that can support physicians and researchers in developing targeted treatment strategies.
The collaboration comes at a time when healthcare systems and research institutions worldwide are investing heavily in precision medicine initiatives. Cancer remains one of the leading causes of death globally, and despite significant therapeutic advances, many patients continue to face limited treatment options due to tumor heterogeneity and resistance to existing therapies. Researchers increasingly believe that combining AI technologies with molecular profiling may provide a pathway toward more effective and individualized cancer treatments.
Japan has emerged as an important market for precision oncology research due to its advanced healthcare infrastructure, strong biomedical research community, and growing focus on innovative therapies. The expanded partnership between BostonGene and Hokkaido University aligns with national efforts to strengthen genomic medicine programs and accelerate the adoption of advanced diagnostics and personalized treatment approaches.
Yukimasa Shiotsu, President and Representative Director of BostonGene Japan, stated that the collaboration demonstrates how AI-driven insights can help bridge the gap between scientific discovery and clinical application.
This partnership exemplifies how BostonGene’s AI-driven insights translate complex patient data into meaningful advances in drug development and clinical care,” Shiotsu said. “It also reinforces our commitment to advancing translational oncology in Japan, where there is significant and urgent clinical need.”
The initiative is expected to support both clinical research and pharmaceutical innovation by generating valuable datasets that may contribute to the development of next-generation cancer therapies. Integrated molecular and immune analyses can help researchers better identify patient populations that are most likely to benefit from specific treatments, potentially improving the success rates of clinical trials and reducing the time required to bring new therapies to market.
In recent years, AI has become an increasingly important tool in biomedical research due to its ability to analyze massive amounts of biological and clinical data with greater speed and precision than traditional analytical methods. AI-powered platforms like BostonGene’s can identify hidden patterns, relationships, and biomarkers that may otherwise remain undetected. This capability is particularly valuable in oncology, where tumor biology is highly complex and varies significantly between patients.
Boston Gene’s AI foundation model of tumor and immune biology integrates genomic, transcriptomic, immune, and clinical data to provide disease-level insights that support therapeutic decision-making. The company works with leading biopharmaceutical organizations and academic institutions around the world to accelerate precision medicine research and improve outcomes for patients with cancer and immune-mediated diseases.
The company’s platform is designed to create a scalable AI-driven decision layer for healthcare and drug development. By optimizing patient selection, trial design, and treatment strategies, BostonGene aims to improve clinical outcomes while enhancing the efficiency of pharmaceutical research and development programs.
Meanwhile, BostonGene Japan continues to expand its role in advancing personalized medicine within the Japanese healthcare market. The Tokyo-based joint venture, formed by BostonGene, NEC Corporation, and Japan Industrial Partners, focuses on leveraging AI-powered multiomics technologies to support drug development and personalize cancer therapies for individual patients.
The collaboration with Hokkaido University highlights the growing role of partnerships between academic institutions and technology-driven healthcare companies in accelerating innovation. Academic medical centers provide access to clinical expertise, patient populations, and scientific research capabilities, while AI and biotechnology companies contribute advanced analytical platforms and computational tools. Together, these collaborations can help drive discoveries that may ultimately transform patient care.
Researchers involved in the initiative hope that the project will contribute to the development of more effective cancer treatments tailored to the biological characteristics of Japanese patients. Since genetic and molecular profiles can vary across populations, region-specific research initiatives are increasingly recognized as essential for advancing precision medicine globally.
As the partnership progresses, the integrated analyses generated through the collaboration may also contribute to future translational research efforts, helping bridge laboratory discoveries with real-world clinical applications. The initiative reflects a broader industry trend toward data-driven healthcare, where advanced analytics and AI technologies are reshaping how diseases are diagnosed, studied, and treated.
With cancer rates continuing to rise worldwide, the demand for innovative precision oncology solutions remains strong. By combining cutting-edge AI technology with comprehensive molecular profiling and academic research expertise, BostonGene and Hokkaido University aim to accelerate the development of personalized therapeutic strategies that can improve survival rates and quality of life for cancer patients in Japan and beyond.
About BostonGene Corporation
BostonGene powers an AI foundation model of tumor and immune biology to deliver disease-level insights and enable precision decision-making across oncology and immune-mediated diseases, spanning drug development and clinical care. By integrating multimodal data, including genomic, transcriptomic, immune, and clinical signals, BostonGene generates biologically grounded intelligence to optimize patient selection, trial design, and therapeutic strategy. This creates a scalable AI decision layer that improves development outcomes and clinical management. BostonGene partners with leading biopharmaceutical organizations and academic institutions to accelerate the delivery of precision therapies while continuously expanding its capabilities across new diseases and complex biological systems.
BostonGene Japan Inc., a Tokyo-based joint venture formed by BostonGene, NEC Corporation and Japan Industrial Partners aims to advance personalized medicine and dramatically improve patient outcomes. The company leverages BostonGene’s AI-powered multiomics platform to accelerate drug development and personalize cancer therapies for each patient.
